NASDAQ:TSRO - TESARO Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TESARO Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.19 million shsAverage Volume1.97 million shsMarket Capitalization$4.13 billionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:TSRO Previous Symbol CUSIP88156910 CIK1491576 Webhttp://www.tesarobio.com/ Phone339-970-0900Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$223.33 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($9.17) Net Income$-496,120,000.00 Net Margins-295.67% Return on Equity-1,209.72% Return on Assets-83.34%Miscellaneous EmployeesN/A Outstanding Shares55,050,000Market Cap$4.13 billion Next Earnings DateN/A OptionableOptionable NASDAQ:TSRO Rates by TradingView Receive TSRO News and Ratings via Email Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter. TESARO (NASDAQ:TSRO) Frequently Asked Questions What is TESARO's stock symbol? TESARO trades on the NASDAQ under the ticker symbol "TSRO." How were TESARO's earnings last quarter? TESARO Inc (NASDAQ:TSRO) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the consensus estimate of ($2.66) by $0.38. The biopharmaceutical company had revenue of $57.21 million for the quarter, compared to analysts' expectations of $65.50 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. TESARO's quarterly revenue was up 94.2% on a year-over-year basis. During the same period in the previous year, the company earned ($2.82) earnings per share. View TESARO's Earnings History. What price target have analysts set for TSRO? 18 Wall Street analysts have issued twelve-month price objectives for TESARO's stock. Their predictions range from $25.00 to $85.00. On average, they anticipate TESARO's share price to reach $66.5714 in the next year. View Analyst Price Targets for TESARO. What is the consensus analysts' recommendation for TESARO? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 15 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TESARO. What are Wall Street analysts saying about TESARO stock? Here are some recent quotes from research analysts about TESARO stock: 1. Cantor Fitzgerald analysts commented, ": 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies." (11/19/2018) 2. According to Zacks Investment Research, "TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2018) Has TESARO been receiving favorable news coverage? Media coverage about TSRO stock has been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TESARO earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for TESARO. Who are some of TESARO's key competitors? Some companies that are related to TESARO include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Array Biopharma (ARRY), Mylan (MYL), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY) and GALAPAGOS NV/S (GLPG). What other stocks do shareholders of TESARO own? Based on aggregate information from My MarketBeat watchlists, some companies that other TESARO investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Clovis Oncology (CLVS), Micron Technology (MU), Celgene (CELG), Tesla (TSLA), Exelixis (EXEL), Gilead Sciences (GILD) and Intel (INTC). Who are TESARO's key executives? TESARO's management team includes the folowing people: Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43) How big of a company is TESARO? TESARO has a market capitalization of $0.00 and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. View Additional Information About TESARO. What is TESARO's official website? The official website for TESARO is http://www.tesarobio.com/. How can I contact TESARO? TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900. MarketBeat Community Rating for TESARO (NASDAQ TSRO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 622 (Thanks for Voting!)Underperform Votes: 478 (Thanks for Voting!)Total Votes: 1,100MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 6/26/2019 by MarketBeat.com StaffFeatured Article: What is the balance sheet?